Clinical Lung Cancer is an Elsevier journal for clinical and translational lung cancer research, from screening and diagnosis to drug resistance and multimodality treatment. Thoracic oncologists and lung cancer researchers read it.
Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles on clinical and translational research in lung cancer, devoted to detection, diagnosis, prevention and treatment with emphasis on recent scientific developments. Its stated areas of interest include clinical research and mechanistic approaches, drug sensitivity and resistance, gene and antisense therapy, pathology, markers and prognostic indicators, chemoprevention strategies, multimodality therapy and integration of approaches. ScienceDirect lists the journal as supporting open access, meaning authors may choose open access or subscription publication. NLM records the title from 1999, first published in Dallas by the Cancer Information Group and from 2011 by Elsevier in New York, bimonthly since July 2002, indexed in MEDLINE and PubMed. Not listed in DOAJ.
Australian oncologist who led DREAM and DREAM3R, testing durvalumab with chemotherapy in mesothelioma.
Lung cancer specialist at Wakayama Medical University who chairs the West Japan Oncology Group cooperative trials network.
Shares Trastuzumab Deruxtecan in Patients From China With Pretreated HER2-Mutant Non-Small Cell Lung Cancer: Final Analysis of the Phase 2, Single-Arm DESTINY-Lung05 Trial, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Nobuyuki Yamamoto, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PubMed & Europe PMC, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PubMed & Europe PMC, Small-cell lung cancer, Non-small-cell lung cancer.
Shares PubMed & Europe PMC, Small-cell lung cancer, Non-small-cell lung cancer.